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Abstract 
Opium is a derivative of opium poppy; the species of plant which its extract is 
used for preparing opium. Opium abuse is considered under drug dependency 
classification of psychiatric diseases and opium abusers have a number of 
major challenges before, during and after anesthesia for surgical operations 
(i.e. the perioperative period). This article reviews these clinical challenges 
during the perioperative period to discuss the new clinical findings for these 
patients and to demonstrate some of the main problems that physicians are 
encountered. 
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Introduction 
Opium is one of the oldest substances being 
abused worldwide. It has been mentioned as an 
anesthetic medication many years ago, including the 
citations to opioid by Shahnameh and Avicenna (1-5). 
However, in the modern medical practice, opioid 
derivatives are used just as their pharmaceutical 
compounds and those patients abusing opium impose 
a great challenge for the medical team especially 
during the course of an operation (3, 6-9). In this 
review, we have focused on the problems related to 
the clinical management of opium abuser patients 
during anesthesia based on the available evidence in 
this field. 
Evidence Acquisition 
The data of this study was gained through a 
systematic search in PubMed. The search strategy 
included the following keywords: opium, anesthesia, 
and anesthesiology. This search was limited to the last 
10 years i.e. from 2005 to 2015. For “(opium) AND 
(anesthesia)”, the search resulted in 35 items while for 
“(opium) AND (anesthesiology)” the search resulted 
in 31 manuscripts. Then, the overlaps between the 
two search results were cleared and the final number 
of manuscripts without being repeated in search query 
was 50. Throughout the study, we found 40 
complementary articles which were in direct relation 
during the search to the primary 45 articles; so they 
were added to our primary sample and finally we had 
95 articles related to “(opium) OR (anesthesia)” or 
“(opium) OR (anesthesiology)”. 
Discussion 
Based on the available evidence, we 
categorized the current studies. For this purpose, we 
will discuss: 
1. Basic studies related to problems of opium 
abuser in anesthesia; which is primarily involved with 
those researches in basic science 
1-1- Genetic factors in pain management for 
opium abusers 
1-2- Receptor response in pain management for 
opium abusers 
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1-3- Immunologic mechanisms for pain 
management in opium abusers 
1-4- Anatomic classification for pain control in 
opium abuser 
2. Then, we have described the clinical 
challenges of opium abusers in anesthesia; so, we 
have used the time course of patient management 
during a surgical operation as the basis for the clinical 
classification: 
2-1- preoperative period: before the operation 
2-2- intraoperative period: at the time of the 
surgical procedure 
2-3- postoperative period: after surgery 
1- Basic studies related to problems of opium 
abuser in anesthesia 
These studies explain how chronic opium 
abuse causes a number of cellular changes in pain 
perception. First we discuss mechanism based 
changes, then, we consider 3 anatomic sources for 
pain control: brain, spinal cord and peripheral nerves. 
Although these studies have been classified here in a 
number of sub-classes, often these classifications 
have overlaps. 
1-1- Genetic factors in pain management for 
opium abusers:  
there are a number of genes that predispose 
people to opium abuse; these genes are the focus for 
further studies; we should believe in “genetic 
predisposition” when treating opium abusers during 
the perioperative period. Also, manipulating these 
genes could be a potential, but very effective method 
for changing the behavioral patterns of opium 
abusers. Possibly, in near future, we could at least 
detect these genes to treat opium abusers undergoing 
anesthesia in a more appropriate manner or even, we 
will be able to produce much more appropriate 
pharmacologic agents for managing opium abusers 
undergoing anesthesia (10-12) 
1-2- Receptor response in pain management for 
opium abusers:  
It is including the changes in neural receptors 
that have occurred in opium abusers. These changes 
affect the pain receptors at the cellular and sub-
cellular level. In other words, the receptors of opium 
have changed their response from a normal response 
to pain to an abnormal response. These changes have 
a number of mechanisms, resulting from the reaction 
of receptors to repeated opium exposure; i.e. opium 
attachment to the receptor does not elicit the normal 
intracellular RNA production process; which would 
result in synthesis of different and abnormal proteins; 
the resulting change in protein synthesis causes 
different clinical responses like pain intolerance, 
hyperalgesia, allodynia or other clinical phenomena 
seen in these patients which are primarily due to 
modifications in receptor response; these mechanisms 
are under further research and contribute an active 
field of studies which could create new horizons not 
only for opium abusers but also for other chronic pain 
patients and include: up-regulation of substance P, up-
regulation of Calcium Gene Related Peptide (CGRP), 
changes in inhibition of Nitric Oxide, modifications in 
inhibitors of cyclooxygenase, abnormal inhibition of 
Protein kinase C, modifications in antagonistic 
response of NMDA (N-methyl-D-aspartate) receptor, 
changes in antagonism of alpha-amino-3-hydroxy-5-
methyl-4 isoxazolepropionic acid (AMPA) receptor, 
antagonism of cholecystokinin (CCK), changes in L-
type Calcium channel response (L-type Ca channel 
could be blocked with amlodipine to overcome some 
effects of opium tolerance) (13-17). 
1-3- Immunologic mechanisms for pain 
management in opium abusers:  
It includes the interactions of the immune 
system due to repeated opium exposure. In opium 
abusers, there are a number of well demonstrated 
changes in immunologic mediators. Immunologic 
cells and other components of the immunologic 
system can induce pain intolerance. Some major 
immunologic responses in opium abusers include: 
increased ratio of pro-inflammatory interleukins 
compared to anti-inflammatory interleukins, 
expression of NK-1 receptor in the dorsal horn of the 
spine, facilitating pain conduction, the role of Toll-
like receptors especially TLR-5 in chronic pain and its 
modulation and other components of both innate and 
adaptive immunology system.  
These changes will results in partial 
ineffectiveness of anesthetic agents, needing extra-
normal anesthetic drugs or inability to control stress 
response which its control is an important goal in 
anesthesia care during perioperative period (18-21). 
1-4- Anatomic classification for pain control in 
opium abusers:  
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It includes brain, spinal cord and peripheral 
nerves. 
Brain related mechanisms: these are due to 
changed response of brain to neurotransmitters, 
cellular signal transduction, signal processing and 
other neural circuit changes in the brain leading at 
times to partially permanent trophic changes that 
result in really great challenges in the clinical field. 
These changes create an abnormal pattern of signal 
transmission in different parts of brain including 
thalamus, locus coeruleus and other nuclei. For 
example: changes in cholecystokinin level in the 
rostral ventromedial medulla in repeated exposure to 
opioids results in up-regulation of CCK; increased 
CCK will activate facilitation of descending pain 
pathways, which is relayed via the dorsolateral 
funiculus, leading to hyperalgesia (13, 17, 22-24), the 
neurons located in locus coeruleus have specific 
relation with mu receptor and they are coupled with K 
channels; while, increased excitatory 
neurotransmission through nucleus 
paragigantocellularis could be among the mechanisms 
that make opium tolerance more severe (13, 22-25), 
opium by itself could induce brain apoptosis which 
may be associated with defects in some parts of brain 
function (26) 
neuroplastic and neurotrophic changes are 
those cellular level changes due to repeated opium 
exposure that show themselves as different response 
to opium and opioid agents; these changes are not as 
much severe as apoptosis; however, they create 
abnormal patterns of brain function and are so called 
“pronociceptive changes” (27, 28). 
Spinal cord related mechanisms: these are 
including ascending and descending pathways in the 
spinal cord and also, local spinal neuronal circuits. 
Generally speaking, we could classify them into the 
following mechanisms: pain elicited through 
descending facilitation which is a main source of 
spinal cord-elicited pain in opium abusers (17, 29), 
up-regulation of spinal dynorphin which could also 
have interactions with bradykinin receptors; the final 
result would be aggravated hyperalgesia with 
neuroexcitatory effect and the resulting 
pronociceptive pain in the spinal cord (29, 30), 
excitatory neurotransmitters which their release 
induces severe pain through spinal cord mechanisms 
(29, 30), role of mitogen activated protein kinase 
(MAP kinase) family, especially the role of TGF-β 
activated kinase 1 in inducing pain through spinal 
cord (16, 30). 
peripheral nervous system related 
mechanisms: the peripheral nerves are subject to 
important changes in opium abusers that mandate 
more sophisticated attention; the current trend of 
research is focused on “silencing” the peripheral 
nerves to improve quality of anesthesia; though the 
majority of these findings are still in the research 
phase and have not entered the clinical era (31, 32); 
these research studies mainly involve: transient 
receptor potential (TRP) channel family especially 
TRPV1 (transient receptor potential vanilloid 1) 
antagonists and TRPA1 transient receptor potential 
ankyrin (TRPA1) antagonists; it is now demonstrated 
that pain signaling in peripheral nerves is mainly done 
through molecular detectors or transducers of TRP 
family (especially TRPV1 and TRPA1) and this is 
why TRPV1 antagonists and TRPA1 antagonists have 
a great role in pain control; in opium abusers we will 
use possibly in the next years such these drugs to 
overcome their pain management challenge; some 
drugs like N-ethyl lidocaine (QX-314) or capsaicin-
derived pharmacologic agents work through these 
channels (32-34), Toll-like receptor (TLR) 5 
stimulation which is among the very novel therapies 
for pain management in some chronic pain patients 
like opium abusers; which treats pain by targeting 
TLR-5 in peripheral nerve endings. Molecules like 
odanacatib (ODN; a cathepsin K inhibitor), flagellin 
or QX-314 act through these mechanisms (20, 34-36). 
Preoperative period: before the operation 
The opium abuser patients often have a number 
of comorbidities, including increased risk for 
cardiovascular disease especially coronary artery 
disease and other cardiac problems (6, 37-40), 
respiratory problems especially periods of hypoxia 
and lung cancers, obstructive and restrictive diseases 
of the lungs (6, 41-44), nutritional and gastrointestinal 
comorbidities including a wide range of lesions 
starting from erosions and lesions in the upper GI 
tract to peptic ulcers and increased occurrence of GI 
cancers (45-48); also, other system diseases (all 
related to abuse of opium) are more frequently seen in 
preoperative evaluation of these patients. In general, 
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opium abusers are more critical compared with 
general population regarding health issues (49). These 
studies have demonstrated that patients with history 
of opium abuse are at increased risk for underlying 
diseases which is a challenging issue for 
anesthesiologists who have to manage the patient and 
to prepare the patient for the operation (3, 6, 37). 
Intraoperative period: at the time of the surgical 
procedure 
During the operation, opium abusers need 
increased anesthetic drugs to tolerate surgery; in fact, 
the studies related to these patients have demonstrated 
some clinical findings that confirm the findings in 
animal studies or other basic researches: chronic 
opium abuse is a major etiology for receptor changes 
regarding sensation and pain perception through 
different mechanisms explained in previous 
paragraphs. These changes make the opium abusers 
more resistant to both opioid analgesics and non-
opioid analgesics (like local anesthetics); a clinical 
finding in concordance with other studies 
demonstrating the effects of chronic opium abuse on 
the cellular mechanisms of pain sensation and the 
bizarre, wide changes in the pain perception structures 
of opium abusers (50-58). 
The problem with these patients during the 
intraoperative period is that excessive opioid use 
results in increased chance for postoperative apnea 
and also, delayed emergence from anesthesia after 
termination of surgery (59). However, a number of 
other anesthetic drugs have been used successfully in 
opium abusers with good results; including ketamine, 
dexmedetomidine and clonidine in order to replace 
the commonly used analgesic agents, i.e. opioid 
derivative (51, 60-63): 
• Dexmedetomidine: among the above, 
dexmedetomidine could be really promising with both 
opium sparing effects and CNS protecting 
mechanisms. Dexmedetomidine decreases the needed 
analgesic requirements in the perioperative period and 
also, has the property to manage opium abusers 
during perioperative period; especially the opioid 
induced hyperalgesia phenomenon; studies have 
demonstrated that dexmedetomidine could be used for 
treatment of opium withdrawal syndrome (64-68). 
• Clonidine has similar chemical properties 
with dexmedetomidine while it is not exactly the 
same; however, clonidine and lofexidine, both alpha 2 
agonists, could be used for treatment of opium 
withdrawal in opium abusers (67, 69). 
• Ketamine could be used in opium abusers 
with fewer respiratory depression events leading to 
opioid sparing results; however, pain control with 
ketamine may be associated with a number of 
delirious states that should elicit cautious when using 
this agent; the clinical solution is to use ketamine as 
low dose and infusion in order to prevent the 
untoward effects as much as possible and to have 
appropriate analgesic properties (51, 60, 70). 
• Paracetamol has an efficacious profile for 
these patients acting through non-opioid analgesic 
mechanisms. 
In opium abusers, there is an alternative 
approach, and this alternative approach is to use 
regional anesthesia; including spinal, epidural and 
other methods of regional anesthesia; however, the 
growing bulk of evidence demonstrates that opium 
abusers have cross-tolerance to local anesthetics, 
mainly including lidocaine and bupivacaine; although, 
the mechanism for tolerance is similar between these 
agents and possibly other forms of local anesthetics 
are similar regarding the tolerance phenomenon; this 
clinical and pharmacological phenomenon presents 
clinically as shortened duration of action (23, 50, 52, 
54, 71). This cross tolerance is a very real problem, 
encountered both clinically and proved in basic 
studies; the underlying mechanism stands on the basis 
of the plastic neuronal changes in the spinal cord 
which create tolerance to both opioids and local 
anesthetics (50, 52, 53). 
A number of adjuvant drugs have been used 
with relatively successful results leading to improved 
regional anesthesia duration and increased analgesic 
properties; some studies focus on adjuvant drugs to 
local anesthetics in order to improve their length of 
analgesia in opium abusers to overcome the rescue 
analgesia properties (53, 72-80): first of all, opioids 
combined with local anesthetics in regional anesthesia 
improve the analgesic potency and decrease the 
rescue analgesic requirements, the safety profiles for 
most of these drugs are well established; however, 
sometimes we need to be more cautious to consider 
their safety profile, other pharmaceuticals, including 
magnesium sulfate, neostigmine, dexmedetomidine, 
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paracetamol, midazolam and others agents have been 
used for regional anesthesia with acceptable levels of 
success (53, 61, 62, 81-85). 
Final problem with opium is that it may be 
“significant allergen” and may create some forms of 
anaphylaxis in operating room; the mechanism of 
allergy is mainly anaphylaxis and other types of 
immune reaction are not much common; at times, 
impaired hemodynamics may ensue; even when 
opium is used as an oral agent and could cause 
hypotension (86, 87). 
Postoperative period: after surgery 
There are a few problems in these patients 
during the postoperative period. First of all, these 
patients need much more analgesic than the others; 
so, care should be given to tailor their analgesic needs 
in such a way that prevents potential respiratory 
problems on one hand and their history of opium 
abuse with the resulting opioid tolerance on the other 
hand. As mentioned above, other drugs are now 
available that could help us manage postoperative 
pain in opium abusers with the use of these “novel, 
non-addictive or less-addictive pain medications” 
leading to decreased use of opium abuse (88). 
However, increased analgesic requirements 
should not lead the management team to consider any 
obligatory withdrawal protocol; since the 
postoperative period is not a suitable clinical interval 
for decreasing the demands of these patients for 
analgesia.  
Nonetheless, the increased pain perception and 
increased analgesic requirements are not the only 
problems with these patients; increased risk of 
postoperative delirium and postoperative cognitive 
disorders are among the other major clinical 
challenges in the postoperative period for these 
patients (89, 90). A number of different agents have 
been introduced (91). Dexmedetomidine is a synthetic 
novel alpha 2 agonist which could help us manage 
these patients in order to reduce opium dose and 
meanwhile, to decrease the chance for postoperative 
cognitive dysfunction (64, 92-94). Other agents like 
midazolam, clonidine or chlorpromazine could also 
be effective when administered as postoperative on-
demand patient controlled analgesia infusion (95). 
 
Conclusion 
Opium abuse is still a major clinical challenge 
and we need work much more in order to improve our 
clinical outcomes; though there are a number of major 
problems during the perioperative period for opium 
abusing patients, still some promising points exist 
which help us look at future with constructive and 
hopeful inspirations; in summary, we can mention the 
followings: 
1- The newly developed drugs like 
dexmedetomidine could improve the future of 
anesthesia for all patients including opium abusers in 
order to decrease the chance of untoward 
complications (like respiratory depression and 
postoperative delirium) while creating good analgesia 
with acceptable level of patient satisfaction. 
2- Other older drugs like clonidine, 
magnesium and ketamine have demonstrated 
relatively good results for opium abusers with opium 
sparing effects. 
3- Regional techniques using local anesthetic 
agents could have more efficacy with the help of 
adjuvant drugs. 
Translational medicine would help us very 
much in near future, possibly by introducing novel 
drugs that treat pain through non-conventional 
methods including cellular and sub-cellular 
modification of pain and also, reversing the effects of 
chronic opium abuse, in order to manage these 
patients more efficiently (21). 
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